Hanmi releases bepotastine orally disintegrating tablets

Published: 2010-04-09 06:56:00

Updated: 2010-04-09 06:56:00

Hanmi says it has recently launched bepotastine calcium (Potastin) in orally disintegrating tablets (ODT), an antihistamine for treatment of allergic rhinitis and uriticaria/puritus.

The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) o...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK